Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
J Am Soc Cytopathol. 2020 Jan-Feb;9(1):55-61. doi: 10.1016/j.jasc.2019.09.003. Epub 2019 Sep 27.
Although uncommon, pulmonary sarcomatoid carcinoma carries a worse prognosis due to poor chemotherapeutic response. Currently, a histologic spindle and/or giant cell component indicates sarcomatoid differentiation, with zinc E-box binding homeobox 1 (ZEB1) implicated in promoting epithelial-mesenchymal transition. However, diagnostic use of ZEB1 in limited specimens, including cell block (CB) preparations, remains unclear.
Pulmonary sarcomatoid (SARC, n = 15), typical (TC, n = 10) and atypical carcinoid (AC, n = 10), small cell (SCLC, n = 8) and large cell neuroendocrine carcinoma (LCNEC, n = 9), squamous cell carcinoma (SQ, n = 7), and adenocarcinoma (ADC, n = 7) CBs along with 69 SARCs, 20 TCs, 21 ACs, 9 SCLCs, 10 LCNECs, 71 SQs, 402 ADCs, 16 large cell carcinoma (LCC) and 17 other thoracic tumor (OT) surgical specimens between 2007 and 2018 were retrieved. ZEB1 (Sigma Aldrich, St. Louis, Mo and Novus Biological, Centennial, Colo) immunohistochemistry was graded 1+ to 3+, with ≥1+ and >5% staining considered positive.
Nuclear ZEB1 was seen in 80% SARC (12/15), 0% TC (0/10), 0% AC (0/10), 12.5% SCLC (1/8) and 11.1% LCNEC (1/9), 0% SQ (0/7), and 0% ADC (0/7) CBs. In surgical specimens, 75.4% SARCs (52/69), 0% TCs (0/20), 0% ACs (0/21), 11.1% SCLCs (1/9), 30% LCNECs (3/10), 0% SQs (0/71), 0.2% ADCs (1/402), 12.5% LCCs (2/16), and 11.8% OTs (2/17) demonstrated ZEB1. ZEB1 sensitivity and specificity in cytology and surgical specimens were 80% and 96.1%, and 75.4% and 98.1%, respectively.
ZEB1 is sensitive and highly specific for pulmonary sarcomatoid carcinoma in limited cytologic and surgical specimens. Diagnostic pitfalls include high-grade neuroendocrine tumors and large cell carcinoma, which are resolvable by morphologic considerations.
尽管不常见,但肺肉瘤样癌由于对化疗反应不佳而预后较差。目前,组织学中的梭形和/或巨细胞成分提示肉瘤样分化,锌指 E 盒结合同源框 1(ZEB1)被认为可促进上皮-间充质转化。然而,ZEB1 在包括细胞块(CB)制剂在内的有限标本中的诊断用途仍不清楚。
收集了 2007 年至 2018 年间的 15 例肺肉瘤样(SARC)、10 例典型(TC)、10 例非典型类癌(AC)、8 例小细胞癌(SCLC)、9 例大细胞神经内分泌癌(LCNEC)、7 例鳞状细胞癌(SQ)和 7 例腺癌(ADC)的 CB 以及 69 例 SARC、20 例 TC、21 例 AC、9 例 SCLC、10 例 LCNEC、71 例 SQ、402 例 ADC、16 例大细胞癌(LCC)和 17 例其他胸部肿瘤(OT)手术标本。使用 Sigma Aldrich(密苏里州圣路易斯)和 Novus Biological(科罗拉多州森特尼尔)的 ZEB1(免疫组化)进行评分,评分为 1+至 3+,≥1+和>5%染色被认为是阳性。
在 CB 标本中,80%的 SARC(12/15)、0%的 TC(0/10)、0%的 AC(0/10)、12.5%的 SCLC(1/8)和 11.1%的 LCNEC(1/9)、0%的 SQ(0/7)和 0%的 ADC(0/7)显示细胞核 ZEB1。在手术标本中,75.4%的 SARC(52/69)、0%的 TC(0/20)、0%的 AC(0/21)、11.1%的 SCLC(1/9)、30%的 LCNEC(3/10)、0%的 SQ(0/71)、0.2%的 ADC(1/402)、12.5%的 LCC(2/16)和 11.8%的 OT(2/17)显示 ZEB1。ZEB1 在细胞学和手术标本中的敏感性和特异性分别为 80%和 96.1%,75.4%和 98.1%。
ZEB1 在有限的细胞学和手术标本中对肺肉瘤样癌具有敏感性和高度特异性。诊断陷阱包括高级别神经内分泌肿瘤和大细胞癌,可通过形态学考虑来解决。